Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + ruxolitinib + retifanlimab
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Trametinib + ruxolitinib + retifanlimab** is a three-drug combination investigated for the treatment of metastatic pancreatic ductal adenocarcinoma. - **Trametinib** is a selective inhibitor of MEK1 and MEK2, integral components of the MAPK/ERK kinase pathway, blocking cell proliferation signals. - **Ruxolitinib** inhibits Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), thereby suppressing the JAK/STAT signaling pathway involved in tumor cell survival and immune evasion. - **Retifanlimab** is a monoclonal antibody that blocks programmed cell death protein 1 (PD-1), thereby restoring T-cell mediated anti-tumor immune responses. Their combined use is designed to provide triple blockade of tumor growth and immune evasion mechanisms: targeted kinase inhibition and immune checkpoint inhibition. This combination is currently being investigated in phase 1 clinical trials[1][2][3][8].
- Other names
- trametinibruxolitinibretifanlimab
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)PDCD1 (Programmed cell death protein 1 receptor)JAK1 (Janus kinase 1)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on trametinib + ruxolitinib + retifanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + ruxolitinib + retifanlimab.